{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:32:42Z","timestamp":1790771562054,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","award":["NCC-1911274"],"award-info":[{"award-number":["NCC-1911274"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ygyno.2021.12.013","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T01:15:49Z","timestamp":1639703749000},"page":"415-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical outcomes of BRCA1\/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer"],"prefix":"10.1016","volume":"164","author":[{"given":"Hyeong In","family":"Ha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Jin","family":"Eoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Jee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Soo","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sokbom","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Yoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myong Cheol","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2021.12.013_bb0005","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","article-title":"Ovarian cancer","volume":"374","author":"Hennessy","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2021.12.013_bb0010","article-title":"Incidence of cervical, endometrial, and ovarian cancer in Korea during 1999\u20132015","volume":"30","author":"Lim","year":"2018","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.12.013_bb0015","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.molonc.2009.02.001","article-title":"The contribution of BRCA1 and BRCA2 to ovarian cancer","volume":"3","author":"Ramus","year":"2009","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ygyno.2021.12.013_bb0020","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ygyno.2021.12.013_bb0025","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/cncr.11310","article-title":"Improved survival in women with BRCA-associated ovarian carcinoma","volume":"97","author":"Cass","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2021.12.013_bb0030","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA."},{"key":"10.1016\/j.ygyno.2021.12.013_bb0035","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nrc3181-c3","article-title":"BRCA1 and BRCA2: important differences with common interests","volume":"12","author":"Roy","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2021.12.013_bb0040","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/ng1295-428","article-title":"Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype\u2013phenotype correlation","volume":"11","author":"Gayther","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2021.12.013_bb0045","first-page":"329","article-title":"Variation in BRCA1 cancer risks by mutation position","volume":"11","author":"Thompson","year":"2002","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.ygyno.2021.12.013_bb0050","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/ng0197-103","article-title":"Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene","volume":"15","author":"Gayther","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2021.12.013_bb0055","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jama.2014.5985","article-title":"Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer","volume":"313","author":"Rebbeck","year":"2015","journal-title":"JAMA."},{"key":"10.1016\/j.ygyno.2021.12.013_bb0060","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/318181","article-title":"Variation in cancer risks, by mutation position, in BRCA2 mutation carriers","volume":"68","author":"Thompson","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ygyno.2021.12.013_bb0065","doi-asserted-by":"crossref","first-page":"23899","DOI":"10.1074\/jbc.C000276200","article-title":"The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin","volume":"275","author":"Bhattacharyya","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ygyno.2021.12.013_bb0070","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1158\/0008-5472.CAN-08-0088","article-title":"Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance","volume":"68","author":"Swisher","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2021.12.013_bb0075","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1200\/JCO.2016.70.4627","article-title":"Reversion of BRCA1\/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer","volume":"35","author":"Christie","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.12.013_bb0080","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation\u2013positive women with ovarian cancer: a report from the Australian ovarian cancer study group","volume":"30","author":"Alsop","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.12.013_bb0085","doi-asserted-by":"crossref","first-page":"6947","DOI":"10.21873\/anticanres.13073","article-title":"Distinct clinical courses of epithelial ovarian cancer with mutations in BRCA1 5\u2019and 3\u2019exons","volume":"38","author":"Eoh","year":"2018","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2021.12.013_bb0090","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/1078-0432.CCR-17-2136","article-title":"Location of mutation in BRCA2 gene and survival in patients with ovarian cancer","volume":"24","author":"Labidi-Galy","year":"2018","journal-title":"Clin. Cancer Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821016395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821016395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:59:03Z","timestamp":1758772743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821016395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0090825821016395"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.12.013","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes of BRCA1\/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}